Open Access546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
Author(s) -
Randolph P. Matthews,
Deanne Jackson Rudd,
Kerry L. Fillgrove,
Sabrina FoxBosetti,
Vanessa Levine,
Sandra Zhang,
Charles Tomek,
Aubrey Stoch,
Marian Iwamoto
Publication year - 2018
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofy210.554
Subject(s) - cyp3a4 , pharmacology , placebo , cmax , pharmacokinetics , reverse transcriptase inhibitor , drug interaction , medicine , cyp2d6 , cytochrome p450 , human immunodeficiency virus (hiv) , virology , viral load , metabolism , alternative medicine , pathology , antiretroviral therapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom